drugset / Trial / NCT01453179
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
Phase 4
Completed
221 enrolled
MEDA Pharma GmbH & Co. KG
Accovion GmbH · collabSiro Clinpharm Germany GmbH (until June 2013) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp. In particular, it should be found out whether the healing effect of these two medications on the skin lesions (i.e. the damaged skin parts) can be maintained for a prolonged period.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diclofenac | Other / unclassified | 3 % | Topical |
| Comparator | Diclofenac | Other / unclassified | 0.5 g | Topical |
| Subject | Imiquimod | Other / unclassified | 5 % | Topical |